I recently went to the AMCP conference last week and attended some insightful presentations. Among all the great talks, one really got me thinking—it was about the role of AI in managed care. The speakers provided examples of how some health plans are already using AI to speed up tasks and streamline processes. But as they talked, I couldn't help but wonder: could AI actually replace the P&T committee down the line? I mean, sure, right now it's not really possible. But imagine if it were. It could make things much easier for pharmacists and everyone involved in the decision-making process. But then again, would we lose something important if we let AI take over completely?
Let's break it down. Looking at it from the pharma manufacturers' and payers' perspectives, an AI-driven P&T process could bring some serious benefits, like making things more predictable and cutting down on potential bias. But then there's the flip side—AI might miss out on the subtleties that humans can pick up on, especially when it comes to new and complex treatments. Think about it: with treatments evolving so quickly, sometimes there's not a ton of data to go on. Would AI be able to handle those situations as well as humans can? It's a tough call. We've got to weigh the efficiency gains against the risk of overlooking important factors.
So, what's the bottom line? Would letting AI make P&T decisions actually lead to better outcomes? It's a big question with no easy answer.